Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus

Diabetology and Metabolic Syndrome

Volumn 9, Issue 1, 2017, Pages

  Yagi, Shusuke ^a,b   Hirata, Yukina ^c   Ise, Takayuki ^a   Kusunose, Kenya ^a   Yamada, Hirotsugu ^a   Fukuda, Daiju ^a   Salim, Hotimah Masdan ^a   Maimaituxun, Gulinu ^a   Nishio, Susumu ^c   Takagawa, Yuriko ^a   Hama, Saori ^a   Matsuura, Tomomi ^a   Yamaguchi, Koji ^a   Tobiume, Takeshi ^a   Soeki, Takeshi ^a   Wakatsuki, Tetsuzo ^a   Aihara, Ken Ichi ^a   Akaike, Masashi ^a   Shimabukuro, Michio ^a,d   Sata, Masataka ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b Department of Pediatric Surgery   (Japan)

^c TOKUSHIMA UNIVERSITY HOSPITAL   (Japan)

^d FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Echocardiography; Epicardial adipose tissue; SGLT2 inhibitors

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; BIGUANIDE DERIVATIVE; CANAGLIFLOZIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLITAZONE DERIVATIVE; HEMOGLOBIN A1C; INSULIN; SULFONYLUREA DERIVATIVE;

ADD ON THERAPY; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; EPICARDIAL FAT; FEMALE; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INTRAPERITONEAL FAT; MALE; MIDDLE AGED; MUSCLE MASS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SUBCUTANEOUS FAT; TREATMENT DURATION;

EID: 85030465923     PISSN: None     EISSN: 17585996     Source Type: Journal    
DOI: 10.1186/s13098-017-0275-4     Document Type: Article

References (32)

1. Rosito GA, Massaro JM, Hoffmann U, Ruberg FL, Mahabadi AA, Vasan RS, et al. Pericardial fat, visceral abdominal fat, cardiovascular disease risk factors, and vascular calcification in a community-based sample: the Framingham Heart Study. Circulation. 2008;117:605-13.
2. Mahabadi AA, Massaro JM, Rosito GA, Levy D, Murabito JM, Wolf PA, et al. Association of pericardial fat, intrathoracic fat, and visceral abdominal fat with cardiovascular disease burden: the Framingham Heart Study. Eur Heart J. 2009;30:850-6.
3. Mahabadi AA, Lehmann N, Kalsch H, Robens T, Bauer M, Dykun I, et al. Association of epicardial adipose tissue with progression of coronary artery calcification is more pronounced in the early phase of atherosclerosis: results from the Heinz Nixdorf recall study. JACC Cardiovasc Imaging. 2014;7:909-16.
4. Shimabukuro M, Hirata Y, Tabata M, Dagvasumberel M, Sato H, Kurobe H, et al. Epicardial adipose tissue volume and adipocytokine imbalance are strongly linked to human coronary atherosclerosis. Arterioscler Thromb Vasc Biol. 2013;33:1077-84.
5. Akoumianakis I, Tarun A, Antoniades C. Perivascular adipose tissue as a regulator of vascular disease pathogenesis: identifying novel therapeutic targets. Br J Pharmacol. 2016;174:3411-24.
6. Narumi T, Watanabe T, Kadowaki S, Otaki Y, Takahashi H, Arimoto T, et al. Increased epicardial adipose tissue volume predicts presence of insulin resistance and coronary artery disease in non-obese subjects without metabolic syndrome. IJC Metabolic and Endocrine. 2014;3:14-9.
7. Iacobellis G, Leonetti F. Epicardial adipose tissue and insulin resistance in obese subjects. J Clin Endocr Metab. 2005;90:6300-2.
8. Rabkin SW, Campbell H. Comparison of reducing epicardial fat by exercise, diet or bariatric surgery weight loss strategies: a systematic review and meta-analysis. Obes Rev. 2015;16:406-15.
9. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. NEng J Med. 2015;373:2117-28.
10. Cefalu WT, Leiter LA, Yoon KH, Arias P, Niskanen L, Xie J, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013;382:941-50.
11. Merovci A, Solis-Herrera C, Daniele G, Eldor R, Fiorentino TV, Tripathy D, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Investig. 2014;124:509-14.
12. Bouchi R, Terashima M, Sasahara Y, Asakawa M, Fukuda T, Takeuchi T, et al. Luseogliflozin reduces epicardial fat accumulation in patients with type 2 diabetes: a pilot study. Cardiovasc Diabetol. 2017;16:32.
13. Fukuda T, Bouchi R, Terashima M, Sasahara Y, Asakawa M, Takeuchi T, et al. Ipragliflozin reduces epicardial fat accumulation in non-obese type 2 diabetic patients with visceral obesity: a pilot study. Diabetes Ther. 2017;8:851-61.
14. Bundhun PK, Janoo G, Huang F. Adverse drug events observed in patients with type 2 diabetes mellitus treated with 100 mg versus 300 mg canagliflozin: a systematic review and meta-analysis of published randomized controlled trials. BMC Pharmacol Toxicol. 2017;18:19.
15. Hirata Y, Yamada H, Kusunose K, Iwase T, Nishio S, Hayashi S, et al. Clinical utility of measuring epicardial adipose tissue thickness with echocardiography using a high-frequency linear probe in patients with coronary artery disease. J Am Soc Echocardiog. 2015;28:1240-6.
16. Yagi S, Kadota M, Aihara K, Nishikawa K, Hara T, Ise T, et al. Association of lower limb muscle mass and energy expenditure with visceral fat mass in healthy men. Diabetol Metabol Syndr. 2014;6:27.
17. Park KS, Lee DH, Lee J, Kim YJ, Jung KY, Kim KM, et al. Comparison between two methods of bioelectrical impedance analyses for accuracy in measuring abdominal visceral fat area. J Diabetes Complicat. 2016;30:343-9.
18. Jensky-Squires NE, Dieli-Conwright CM, Rossuello A, Erceg DN, McCauley S, Schroeder ET. Validity and reliability of body composition analysers in children and adults. Brit J Nutr. 2008;100:859-65.
19. Sacks HS, Fain JN. Human epicardial adipose tissue: a review. Am Heart J. 2007;153:907-17.
20. Iacobellis G, Singh N, Wharton S, Sharma AM. Substantial changes in epicardial fat thickness after weight loss in severely obese subjects. Obesity. 2008;16:1693-7.
21. Kim MK, Tomita T, Kim MJ, Sasai H, Maeda S, Tanaka K. Aerobic exercise training reduces epicardial fat in obese men. J Appl Physiol. 2009;106:5-11.
22. Park JH, Park YS, Kim YJ, Lee IS, Kim JH, Lee JH, et al. Effects of statins on the epicardial fat thickness in patients with coronary artery stenosis underwent percutaneous coronary intervention: comparison of atorvastatin with simvastatin/ezetimibe. J Cardiovasc Ultrasound. 2010;18:121-6.
23. Takase H, Dohi Y, Okado T, Hashimoto T, Goto Y, Kimura G. Effects of ezetimibe on visceral fat in the metabolic syndrome: a randomised controlled study. Eur J Clin Invest. 2012;42:1287-94.
24. Marchington JM, Pond CM. Site-specific properties of pericardial and epicardial adipose tissue: the effects of insulin and high-fat feeding on lipogenesis and the incorporation of fatty acids in vitro. Int J Obes. 1990;14:1013-22.
25. Dagvasumberel M, Shimabukuro M, Nishiuchi T, Ueno J, Takao S, Fukuda D, et al. Gender disparities in the association between epicardial adipose tissue volume and coronary atherosclerosis: a 3-dimensional cardiac computed tomography imaging study in Japanese subjects. Cardiovasc Diabetol. 2012;11:106.
26. Maimaituxun G, Shimabukuro M, Salim HM, Tabata M, Yuji D, Morimoto Y, et al. Gender-linked impact of epicardial adipose tissue volume in patients who underwent coronary artery bypass graft surgery or non-coronary valve surgery. PLoS ONE. 2017;12:e0177170.
27. Iacobellis G, Willens HJ. Echocardiographic epicardial fat: a review of research and clinical applications. J Am Soc Echocardiog. 2009;22:1311-9.
28. Natale F, Tedesco MA, Mocerino R, de Simone V, Di Marco GM, Aronne L, et al. Visceral adiposity and arterial stiffness: echocardiographic epicardial fat thickness reflects, better than waist circumference, carotid arterial stiffness in a large population of hypertensives. Eur J Echocardiogr. 2009;10:549-55.
29. Nishio S, Kusunose K, Yamada H, Hirata Y, Ise T, Yamaguchi K, et al. Echocardiographic epicardial adipose tissue thickness is associated with symptomatic coronary vasospasm during provocative testing. J Am Soc Echocardiogr 2017.doi: 10.1016/j.echo.2017.06.024.
30. Wu FZ, Chou KJ, Huang YL, Wu MT. The relation of location-specific epicardial adipose tissue thickness and obstructive coronary artery disease: systemic review and meta-analysis of observational studies. BMC Cardiovasc Disord. 2014;14:62.
31. Davies MJ, Trujillo A, Vijapurkar U, Damaraju CV, Meininger G. Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2015;17:426-9.
32. Chino Y, Samukawa Y, Sakai S, Nakai Y, Yamaguchi J, Nakanishi T, et al. SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria. Biopharm Drug Dispos. 2014;35:391-404.